Regulatory Q&A Forum
Ask questions, share knowledge, and get help from the regulatory community
With significant revisions to the ISO 10993 series anticipated around 2026, how should medical device manufacturers strategically adapt their biocompatibility evaluation process, moving beyond a simpl...
For medical device manufacturers based outside the United Kingdom, appointing a UK Responsible Person (UKRP) is a critical step for market access. While the fundamental requirement is understood, what...
For many Class II medical devices, General Controls alone are insufficient to provide a reasonable assurance of safety and effectiveness. To address this, the FDA establishes Special Controls, which a...
For sponsors of a novel Class II Software as a Medical Device (SaMD), what are the essential components of a comprehensive cybersecurity risk management plan required for a premarket submission? Beyon...
Under the EU Medical Device Regulation (MDR), the role of the Person Responsible for Regulatory Compliance (PRRC) is a critical function for ensuring a manufacturer's ongoing conformity. As the regula...
For non-EU manufacturers preparing for future chemical compliance deadlines in Europe, selecting a REACH Only Representative (OR) is a critical strategic decision that extends far beyond a simple lega...
For sponsors developing software intended for clinical use, what key factors does the FDA consider when determining if the software is a regulated medical device versus a non-device health IT tool? Fo...
With significant revisions to the EU WEEE Directive and other global Extended Producer Responsibility (EPR) frameworks anticipated for 2026, how should medical device manufacturers strategically evalu...
With significant updates to the ISO 10993 standard series anticipated, how should a medical device manufacturer conduct comprehensive due diligence to select a biocompatibility testing laboratory that...
With the FDA’s Quality Management System Regulation (QMSR) set to align 21 CFR 820 with ISO 13485 in 2026, how should medical device manufacturers adjust their approach to biocompatibility evaluation?...
As the United Kingdom's medical device regulatory framework continues to evolve, non-UK manufacturers must prepare for updated requirements concerning the UK Responsible Person (UKRP). What are the ke...
When preparing a premarket submission for a connected medical device, how can a sponsor effectively document their cybersecurity management plan to meet FDA expectations as outlined in guidances like ...
When budgeting for compliance in 2026, how can a company that processes data of EU residents, but has no physical establishment in the EU, evaluate the factors that determine the cost of a GDPR Articl...
As regulations like the upcoming EU Deforestation Regulation (EUDR) highlight the increasing need for non-EU companies to have a legal presence within the Union, medical device manufacturers have long...
For non-EU based medical device or SaMD companies targeting the European market, how should they strategically re-evaluate and select a GDPR Article 27 Representative for 2026 and beyond, moving past ...
What are the key criteria for a non-EU manufacturer when selecting an EU Authorized Representative, particularly in light of new, cross-sectoral regulations like the Carbon Border Adjustment Mechanism...
With the implementation of the Modernization of Cosmetics Regulation Act (MoCRA), foreign cosmetic facilities that manufacture or process products for the U.S. market are now required to designate a U...
Given recent MDCG guidance that provides further clarity on the role and responsibilities of the Person Responsible for Regulatory Compliance (PRRC) under EU MDR, how should medical device manufacture...
For non-EU manufacturers of chemical substances or mixtures preparing for future REACH compliance deadlines, what strategic framework should be used to select an effective and reliable Only Representa...
As the 2026 milestone for full EU Medical Device Regulation (MDR) and In Vitro Diagnostic Regulation (IVDR) implementation approaches, how should a non-EU manufacturer assess a potential EU Authorized...